Roche (RHHBY) expects an increase in Group sales in the mid single digit range. Core earnings per share are targeted to develop in the high single to low double digit range. Roche expects to further increase its dividend in Swiss francs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Trump Trade: Trump administration prepares new probe into pharma prices
- Trump admin prepares new probe into U.S. pharma prices, FT says
- Celcuity price target raised to $95 from $70 at Needham
- Oppenheimer remains bullish on Olema despite ‘Jekyll and Hyde kinda ESMO’
- Genentech announces FDA approval for Gazyva for active lupus nephritis